X4 Pharmaceuticals, Inc Net Income (Loss) Attributable to Parent in USD from 2016 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
X4 Pharmaceuticals, Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2016 to Q3 2025.
  • X4 Pharmaceuticals, Inc Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was -$29.8M, a 18.8% increase year-over-year.
  • X4 Pharmaceuticals, Inc Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was -$95.1M, a 467% decline year-over-year.
  • X4 Pharmaceuticals, Inc annual Net Income (Loss) Attributable to Parent for 2024 was -$37.5M, a 63% increase from 2023.
  • X4 Pharmaceuticals, Inc annual Net Income (Loss) Attributable to Parent for 2023 was -$101M, a 7.78% decline from 2022.
  • X4 Pharmaceuticals, Inc annual Net Income (Loss) Attributable to Parent for 2022 was -$93.9M, a 5.83% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)

X4 Pharmaceuticals, Inc Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$95.1M -$29.8M +$6.88M +18.8% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-05
Q2 2025 -$102M -$25.7M -$117M -128% Apr 1, 2025 Jun 30, 2025 10-Q 2025-11-05
Q1 2025 $14.6M $282K +$52M Jan 1, 2025 Mar 31, 2025 10-Q 2025-11-05
Q4 2024 -$37.5M -$39.8M -$20.7M -108% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-26
Q3 2024 -$16.8M -$36.7M -$34.4M -1492% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-05
Q2 2024 $17.6M $90.8M +$147M Apr 1, 2024 Jun 30, 2024 10-Q 2025-11-05
Q1 2024 -$129M -$51.8M -$27.7M -116% Jan 1, 2024 Mar 31, 2024 10-Q 2025-11-05
Q4 2023 -$101M -$19.1M +$9.97M +34.3% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-26
Q3 2023 -$111M -$2.31M +$19.3M +89.3% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$130M -$55.7M -$34.5M -163% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-13
Q1 2023 -$95.9M -$24M -$2.06M -9.36% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-13
Q4 2022 -$93.9M -$29.1M +$1.1M +3.65% Oct 1, 2022 Dec 31, 2022 10-K 2025-03-26
Q3 2022 -$95M -$21.6M -$1.41M -6.99% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$93.6M -$21.2M -$1.57M -8.02% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$92M -$22M -$3.29M -17.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$88.7M -$30.2M -$11.8M -64.2% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-21
Q3 2021 -$76.9M -$20.2M -$2.73M -15.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$74.2M -$19.6M -$4.49M -29.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-03
Q1 2021 -$69.7M -$18.7M -$7.54M -67.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-03
Q4 2020 -$62.1M -$18.4M -$7.56M -69.8% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-21
Q3 2020 -$54.6M -$17.4M +$265K +1.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$54.8M -$15.1M -$1.76M -13.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-04
Q1 2020 -$53.1M -$11.1M -$265K -2.44% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-04
Q4 2019 -$52.8M -$10.8M -$1.48M -15.8% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-17
Q3 2019 -$51.3M -$17.7M -$9.11M -106% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$42.2M -$13.4M -$7.35M -122% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-05
Q1 2019 -$34.9M -$10.9M -$3.51M -47.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-05
Q4 2018 -$31.4M -$9.36M +$1.83M +16.3% Oct 1, 2018 Dec 31, 2018 10-K 2019-03-11
Q3 2018 -$33.2M -$8.6M +$3M +25.8% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$36.2M -$6.03M -$329K -5.77% Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-07
Q1 2018 -$35.9M -$7.37M -$1.98M -36.8% Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-07
Q4 2017 -$33.9M -$11.2M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-11
Q3 2017 -$11.6M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-11
Q2 2017 -$5.71M Apr 1, 2017 Jun 30, 2017 10-K 2019-03-11
Q1 2017 -$5.39M Jan 1, 2017 Mar 31, 2017 10-K 2019-03-11

X4 Pharmaceuticals, Inc Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$37.5M +$63.7M +63% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-26
2023 -$101M -$7.3M -7.78% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-26
2022 -$93.9M -$5.17M -5.83% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-26
2021 -$88.7M -$26.6M -42.8% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-21
2020 -$62.1M -$9.32M -17.7% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-21
2019 -$52.8M -$19.5M -58.7% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-17
2018 -$33.3M -$11.3M -51.3% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-19
2017 -$22M +$981K +4.27% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-12
2016 -$23M Jan 1, 2016 Dec 31, 2016 10-K 2019-03-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.